	US 12,234,270 B2
	IL-12 heterodimeric Fc-fusion proteins
Matthew Bernett, Monrovia, CA (US); John R. Desjarlais, Pasadena, CA (US); Rajat Varma, Hamden, CT (US); Ke Liu, Glendora, CA (US); Nargess Hassanzadeh-Kiabi, Pasadena, CA (US); and Rumana Rashid, Temple City, CA (US)
Assigned to Xencor, Inc., Pasadena, CA (US)
Filed by Xencor, Inc., Monrovia, CA (US)
Filed on Apr. 11, 2022, as Appl. No. 17/718,087.
Application 17/718,087 is a continuation of application No. 16/592,656, filed on Oct. 3, 2019, granted, now 11,358,999.
Claims priority of provisional application 62/848,512, filed on May 15, 2019.
Claims priority of provisional application 62/810,038, filed on Feb. 25, 2019.
Claims priority of provisional application 62/740,813, filed on Oct. 3, 2018.
Prior Publication US 2022/0396605 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/54 (2006.01); A61K 38/20 (2006.01); A61K 47/68 (2017.01); C07K 19/00 (2006.01); A61K 38/00 (2006.01); C07K 1/18 (2006.01)

CPC C07K 14/5434 (2013.01) [A61K 38/208 (2013.01); A61K 47/6813 (2017.08); C07K 19/00 (2013.01); A61K 38/00 (2013.01); C07K 1/18 (2013.01); C07K 2319/30 (2013.01)]

2 Claims

1. A composition comprising a variant IL-12p40 subunit domain, wherein said variant IL-12p40 subunit domain comprises amino acid substitutions selected from the group consisting of E59K, E59K/K99Y, and E59K/K99Y/C252S, wherein said variant IL-12p40 subunit domain has at least 90% sequence identity to SEQ ID NO: 4.